机构：[1]Honors College, University of Houston, Houston, TX 77204, USA.[2]Key Laboratory of Epigentics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.[3]Department of Pathology, Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, Sichuan 646000, China.[4]Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA 19131, USA.[5]Department of Biology & Biochemistry, University of Houston, Houston, TX 77204, USA.[6]Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX 77030, USA.[7]Judicial Authentication Center, Southwest Medical University, Luzhou, Sichuan 646000, China.
Cancer is genetically heterogeneous regarding to molecular genetic characteristics and pathogenic pathways. A wide spectrum of biomarkers, including DNA markers, is used in determining genomic instability, molecular subtype determination and disease prognosis, and estimating sensitivity to different drugs in clinical practice. In a previous study, we developed highly effective DNA markers using improved random amplified polymorphic DNA (RAPD) with high-GC primers, which is a valuable approach for the genetic authentication of medicinal plants. In this study, we applied this effective DNA marker technique to generate genetic fingerprints that detect genomic alterations in human breast cancer tissues and then developed sequence-characterized amplified region (SCAR) markers. Three SCAR markers (BC10-1, BC13-4 and BC31-2) had high levels of genomic DNA amplification in breast cancer. The PHKG2 and RNF40 genes are either overlapping or close to the sequences of SCAR marker BC13-4, while SCAR marker BC10-1 is in the intron and overlap the DPEP1 gene, suggesting that alterations in the expression of these genes could contribute to cancer progression. Screening of breast cancer cell lines showed that the mRNA expression levels for the PHKG2 and DPEP1 were lower in non-tumorigenic mammary epithelial cell MCF10A, but elevated in other cell lines. The DPEP1 mRNA level in invasive ductal carcinoma specimens was significantly higher than that of the adjacent normal tissues in women. Taken together, high-GC RAMP-PCR provides greater efficacy in measuring genomic DNA amplifications, deletion or copy number variations. Furthermore, SCAR markers BC10-1 and BC13-4 might be useful diagnostic markers for breast cancer carcinomas.
基金：
This work was supported in part by the National Natural Science Foundation of China (81672887, 81172049), the Science and Technology Innovation Team of Colleges and Universities of Sichuan Province (13TD0032), the Applied Basic Research Program of Science and Technology Department of Sichuan Province (14JC0797, 2015JY0038), and the Research Foundation of the Education Department of Sichuan Province (17ZA0427, 17ZB0467).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Honors College, University of Houston, Houston, TX 77204, USA.
共同第一作者：
通讯作者：
通讯机构：[2]Key Laboratory of Epigentics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China.[7]Judicial Authentication Center, Southwest Medical University, Luzhou, Sichuan 646000, China.
推荐引用方式(GB/T 7714)：
Fu Shangyi,Cheng Jingliang,Wei Chunli,et al.Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments.[J].Oncotarget.2017,8(27):43866-43877.doi:10.18632/oncotarget.16704.
APA：
Fu Shangyi,Cheng Jingliang,Wei Chunli,Yang Luquan,Xiao Xiuli...&Fu Junjiang.(2017).Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments..Oncotarget,8,(27)
MLA：
Fu Shangyi,et al."Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments.".Oncotarget 8..27(2017):43866-43877
